Wednesday, 18 Sep 2019

You are here

Nintedanib May Benefit Systemic Sclerosis Related Interstitial Lung Disease

The NEJM reports a randomized placebo controlled trial of nintedanib, a tyrosine kinase inhibitor, in systemic sclerosis patients with interstitial lung disease (ILD) resulted in less pulmonary decline, but had no effect on other features of systemic sclerosis. 

Systemic sclerosis patients were enrolled if within 7 years of disase onset (non-Raynaud’s) and had high-resolution computed tomographic scan showing lung fibrosis affecting at least 10% of the lungs. Patients were randomized to receive 150 mg of nintedanib, administered orally twice daily, or placebo. The primary end point was the annual rate of decline in forced vital capacity (FVC), assessed over 52 weeks. 

Among 576 patients, 52% had diffuse cutaneous systemic sclerosis, and 48.4% were on background mycophenolate.

The prime outcome was the adjusted annual rate of change in FVC change:

  • nintedanib group : −52.4 ml per year
  • placebo group: −93.3 ml per year (difference, 41.0 ml per year; 95% confidence interval [CI], 2.9 to 79.0; P=0.04)

Other outcomes were not significant including the modified Rodnan skin score and the SGRQ at week 52.

Diarrhea, was much more common in those receiving nintedanib (75.7% vs 31.6%).

Nintedanib (Ofev) is currently FDA approved for use in idiopathic pulmonary fibrosis. It may have protective benefits in systemic sclerosis patients who develop ILD, but does not appear to otherwise benefit extrapulmonary disease progression in systemic sclerosis.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Anakinra Shows Benefits in Cytokine Storm

The interleukin (IL)-1 receptor antagonist anakinra (Kineret) showed promise in critically ill children who develop the often-lethal condition known as secondary hemophagocytic lymphohistiocytosis (sHLH)/macrophage activation syndrome (MAS), a retrospective single-center study found.

 

Prior Authorizations Delay Care in Rheumatology

Physicians who believe their patients' health is negatively affected by insurers' demands for prior authorization, and the delays that often result, will find that opinion vindicated by a new study of rheumatology care: when permission had to be sought from insurers to provide intravenous drugs, average time to begin treatment was longer and patients had twice the corticosteroid exposure, a single-center analysis found.

Upadacitinib (RINVOQ) FDA Approved for Rheumatoid Arthritis

The US Food and Drug Administration (FDA) on Friday, August 16, approved AbbVie JAK1 inhibitor, Rinvoq (upadacitinib) for adults with  rheumatoid arthritis with moderately to severely active disease either not responding to, or intolerant of, methotrexate (MTX). 

Are Non-TNF Biologics Superior to TNF inhibitors?

Current ACR and EULAR guidelines list TNF-inhibitors (TNFi) abatacept, rituximab, and tocilizumab as being equally effective after methotrexate or as second line therapies when treating rheumatoid arthritis. An analysis from the Swedish Rheumatology Register shows that the non-TNFi biologic DMARDs (bDMARDs), in particular tocilizumab and rituximab, are more effective than TNFi. 

FINCH2: Filgotinib in Biologic Refractory Rheumatoid Arthritis

The FINCH2 study has shown that filgotinib, an oral once daily JAK 1 inhibitor, is highly effective in rheumatoid arthritis (RA) patients who failed to respond to prior biologic therapy.